-
3
-
-
0001504546
-
From Susie's question to CFC free: An inventor's perspective on forty years of MDI development and regu-lation
-
RN Dalby, PR Byron, and SJ Farr (eds) Interpharm Press, Buffalo Grove, IL
-
Thiel CG: From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regu-lation. In: RN Dalby, PR Byron, and SJ Farr (eds). Re-spiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL; pp. 115-123, 1996.
-
(1996)
Re-spiratory Drug Delivery v
, pp. 115-123
-
-
Thiel, C.G.1
-
4
-
-
34248639855
-
The rejuvenated pressurized me-tered dose inhaler
-
Bell J, and Newman S: The rejuvenated pressurized me-tered dose inhaler. Expert Opin Drug Del. 2007;4:215-234.
-
(2007)
Expert Opin Drug Del
, vol.4
, pp. 215-234
-
-
Bell, J.1
Newman, S.2
-
5
-
-
12344288639
-
Pulmonary delivery technology: Advances and potential for the new millennium
-
AJ Hickey (ed) Marcel Dekker, New York
-
Clark A: Pulmonary delivery technology: advances and potential for the new millennium. In AJ Hickey (ed). Pharamceutical Inhalation Aerosol Technology, 2nd ed. Marcel Dekker, New York; pp. 571-591, 2004.
-
(2004)
Pharamceutical Inhalation Aerosol Technology, 2nd Ed.
, pp. 571-591
-
-
Clark, A.1
-
9
-
-
0011489418
-
Dispersion and characterization of pharmaceutical dry powder aerosols
-
Dunbar CA, Hickey AJ, and Holzner P: Dispersion and characterization of pharmaceutical dry powder aerosols. KONA. 1998;16:7-45.
-
(1998)
KONA
, vol.16
, pp. 7-45
-
-
Dunbar, C.A.1
Hickey, A.J.2
Holzner, P.3
-
11
-
-
20044363723
-
The cohesive-adhesive balances in dry powder inhaler formu-lations I: Direct quantification by atomic force microscopy
-
Begat P, Morton AV, Staniforth JN, and Price R: The cohesive-adhesive balances in dry powder inhaler formu-lations I: direct quantification by atomic force microscopy. Pharm Res. 2004;21:1591-1597.
-
(2004)
Pharm Res
, vol.21
, pp. 1591-1597
-
-
Begat, P.1
Morton, A.V.2
Staniforth, J.N.3
Price, R.4
-
12
-
-
6344245649
-
The cohesive-adhesive balances in dry powder inhaler formulations II: Influences of fine particle delivery charac-teristics
-
Begat P, Morton AV, Staniforth JN, and Price R: The cohesive-adhesive balances in dry powder inhaler formulations II: influences of fine particle delivery charac-teristics. Pharm Res. 2004;21:1826-1833.
-
(2004)
Pharm Res
, vol.21
, pp. 1826-1833
-
-
Begat, P.1
Morton, A.V.2
Staniforth, J.N.3
Price, R.4
-
14
-
-
0034750024
-
Use of solid corrugated par-ticles to enhance powder performance
-
Chew NYK, and Chan H-K: Use of solid corrugated par-ticles to enhance powder performance. Pharm Res. 2001;18: 1570-1577.
-
(2001)
Pharm Res
, vol.18
, pp. 1570-1577
-
-
Nyk, C.1
Chan, H.-K.2
-
15
-
-
73949099876
-
Force control and powder dispersibility of spray dried particles for in-halation
-
Weiler C, Egen M, Trunk M, and Langguth P: Force control and powder dispersibility of spray dried particles for in-halation. J Pharm Sci. 2010;99:303-316.
-
(2010)
J Pharm Sci.
, vol.99
, pp. 303-316
-
-
Weiler, C.1
Egen, M.2
Trunk, M.3
Langguth, P.4
-
16
-
-
10744227569
-
Large porous particles for pulmonary drug delivery
-
Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, and Langer R: Large porous particles for pulmonary drug delivery. Science. 1997; 276:1868-1871.
-
(1997)
Science
, vol.276
, pp. 1868-1871
-
-
Edwards, D.A.1
Hanes, J.2
Caponetti, G.3
Hrkach, J.4
Ben-Jebria, A.5
Eskew, M.L.6
Mintzes, J.7
Deaver, D.8
Lotan, N.9
Langer, R.10
-
17
-
-
67649389317
-
Porous particles for inhalation: The science be-hind their improved dispersibility
-
RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
-
Dunbar C: Porous particles for inhalation: the science be-hind their improved dispersibility. In RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery X. Amy Davis Biggs, River Grove, IL; pp. 307-313, 2006.
-
(2006)
Respiratory Drug Delivery X
, pp. 307-313
-
-
Dunbar, C.1
-
18
-
-
0036803986
-
In vitro and in vivo dose delivery charac-teristics of large porous particles for inhalation
-
Dunbar C, Scheuch G, Sommerer K, DeLong M, Verma A, and Batycky R: In vitro and in vivo dose delivery charac-teristics of large porous particles for inhalation. Int J Pharm. 2002; 245:179-189.
-
(2002)
Int J Pharm
, vol.245
, pp. 179-189
-
-
Dunbar, C.1
Scheuch, G.2
Sommerer, K.3
Delong, M.4
Verma, A.5
Batycky, R.6
-
19
-
-
29844437915
-
Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates
-
DeLong M, Wright J, Dawson M, Meyer T, Sommerer K, and Dunbar C: Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med. 2005;18:452-459.
-
(2005)
J Aerosol Med
, vol.18
, pp. 452-459
-
-
Delong, M.1
Wright, J.2
Dawson, M.3
Meyer, T.4
Sommerer, K.5
Dunbar, C.6
-
20
-
-
0036001409
-
Improved lung delivery from a passive dry powder inhaler using an engineered Pulmo-Sphere powder
-
Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, and Weers JG: Improved lung delivery from a passive dry powder inhaler using an engineered Pulmo-Sphere powder. Pharm Res. 2002;19:689-695.
-
(2002)
Pharm Res
, vol.19
, pp. 689-695
-
-
Duddu, S.P.1
Sisk, S.A.2
Walter, Y.H.3
Tarara, T.E.4
Trimble, K.R.5
Clark, A.R.6
Ma, E.7
Elton, R.C.8
Pickford, M.9
Hirst, P.H.10
Newman, S.P.11
Weers, J.G.12
-
22
-
-
0028316923
-
Long term stabilization of biologics
-
Franks F: Long term stabilization of biologics. Bio/Tech-nology. 1994;12:253-256.
-
(1994)
Bio/Technology
, vol.12
, pp. 253-256
-
-
Franks, F.1
-
23
-
-
0032817957
-
Stabilization of labile materials by amorphous carbohydrates and their derivatives
-
Blair JA, and Hatley RHM: Stabilization of labile materials by amorphous carbohydrates and their derivatives. J Mol Catalysis B: Enzymatic. 1999;7:11-19.
-
(1999)
J Mol Catalysis B: Enzymatic
, vol.7
, pp. 11-19
-
-
Blair, J.A.1
Rhm, H.2
-
24
-
-
0037332149
-
Micro-calorimetric measurement of the interactions between water vapor and amorphous pharmaceutical solids
-
Lechuga-Ballesteros D, Bakri A, and Miller DP: Micro-calorimetric measurement of the interactions between water vapor and amorphous pharmaceutical solids. Pharm Res. 2003;20:308-318.
-
(2003)
Pharm Res
, vol.20
, pp. 308-318
-
-
Lechuga-Ballesteros, D.1
Bakri, A.2
Miller, D.P.3
-
25
-
-
38349089705
-
Trileucine im-proves aerosol performance and stability of spray-dried powders for inhalation
-
Lechuga-Ballesteros D, Charan C, Stults CL, Stevenson CL, Miller DP, Vehring R, Tep V, and Kuo MC: Trileucine im-proves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci. 2008;97:287-302.
-
(2008)
J Pharm Sci
, vol.97
, pp. 287-302
-
-
Lechuga-Ballesteros, D.1
Charan, C.2
Stults, C.L.3
Stevenson, C.L.4
Miller, D.P.5
Vehring, R.6
Tep, V.7
Kuo, M.C.8
-
26
-
-
34248642757
-
^\development of a novel technology solution for pulmonary delivery of insulin
-
RN Dalby, PR Byron, J Peart, and J Suman (eds) Davis Healthcare Int Publishing, LLC, River Grove, IL;
-
^\ development of a novel technology solution for pulmonary delivery of insulin. In: RN Dalby, PR Byron, J Peart, and J Suman (eds). Respiratory Drug Delivery Europe 2005. Davis Healthcare Int Publishing, LLC, River Grove, IL; pp. 225-227, 2005.
-
(2005)
Respiratory Drug Delivery Europe 2005
, pp. 225-227
-
-
White, S.1
Bennett, D.2
Stevenson, C.3
Harper, N.4
-
27
-
-
0025943936
-
Contemporary approaches in aerosolized drug delivery to the lung
-
Gupta PK, and Hickey AJ: Contemporary approaches in aerosolized drug delivery to the lung. J Controlled Rel. 1991;17:129-148.
-
(1991)
J Controlled Rel
, vol.17
, pp. 129-148
-
-
Gupta, P.K.1
Hickey, A.J.2
-
28
-
-
4544325094
-
Controlled release products for respiratory drug delivery
-
Louey MD, and Garcia-Contreas L: Controlled release products for respiratory drug delivery. Am Pharm Rev. 2004;7:82-87.
-
(2004)
Am Pharm Rev
, vol.7
, pp. 82-87
-
-
Louey, M.D.1
Garcia-Contreas, L.2
-
29
-
-
0022539757
-
Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation
-
Byron PR: Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986;75:433-438.
-
(1986)
J Pharm Sci
, vol.75
, pp. 433-438
-
-
Byron, P.R.1
-
30
-
-
0029090267
-
The controlled de-livery of drugs to the lung
-
Zeng, XM, Martin GP, and Marriott C: The controlled de-livery of drugs to the lung. Int J Pharm. 1995;124:149-164.
-
(1995)
Int J Pharm
, vol.124
, pp. 149-164
-
-
Zeng, X.M.1
Martin, G.P.2
Marriott, C.3
-
31
-
-
0033925098
-
Sustained drug delivery to the lungs\an option for the future
-
Hardy JG, and Chadwick TS: Sustained drug delivery to the lungs\an option for the future. Clin Pharmacokinet. 2000;39:1-4.
-
(2000)
Clin Pharmacokinet
, vol.39
, pp. 1-4
-
-
Hardy, J.G.1
Chadwick, T.S.2
-
32
-
-
0034848118
-
Respirable PLGA micro-spheres containing rifampicin for the treatment of tuber-culosis: Screening in an infectious disease model
-
Suarez S, O'Hara P, Kazantseva M, Newcomer C, Hopfer R, McMurray DN, and Hickey AJ: Respirable PLGA micro-spheres containing rifampicin for the treatment of tuber-culosis: screening in an infectious disease model. Pharm Res. 2001;18:1315-1319.
-
(2001)
Pharm Res
, vol.18
, pp. 1315-1319
-
-
Suarez, S.1
O'Hara, P.2
Kazantseva, M.3
Newcomer, C.4
Hopfer, R.5
McMurray, D.N.6
Hickey, A.J.7
-
33
-
-
34547642167
-
Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model
-
Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, and Edwards D: Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007;51:2830-2836.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 2830-2836
-
-
Garcia-Contreras, L.1
Fiegel, J.2
Telko, M.J.3
Elbert, K.4
Hawi, A.5
Thomas, M.6
Verberkmoes, J.7
Germishuizen, W.A.8
Fourie, P.B.9
Hickey, A.J.10
Edwards, D.11
-
34
-
-
0036007839
-
Technosphere/Insulin\proof of concept study with a new insulin formulation for pulmonary drug delivery
-
Steiner S, Pfutzner A, Wilson BR, Harzer O, Heinemann L, and Rave K: Technosphere/Insulin\proof of concept study with a new insulin formulation for pulmonary drug delivery. Exp Clin Endocrinol Diabetes. 2002;110:17-21.
-
(2002)
Exp Clin Endocrinol Diabetes
, vol.110
, pp. 17-21
-
-
Steiner, S.1
Pfutzner, A.2
Wilson, B.R.3
Harzer, O.4
Heinemann, L.5
Rave, K.6
-
35
-
-
0041928149
-
Pilot study with Technosphere/PTH(1-34)\a new approach for effective pulmonary delivery of parathyroid hormone (1-34)
-
Pfutzner A, Flacke F, Pohl R, Linkie D, Engelbach M, Woods R, Forst T, Beyer J, and Steiner SS: Pilot study with Technosphere/PTH(1-34)\a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Horm Metab Res. 2003;35:319-323.
-
(2003)
Horm Metab Res
, vol.35
, pp. 319-323
-
-
Pfutzner, A.1
Flacke, F.2
Pohl, R.3
Linkie, D.4
Engelbach, M.5
Woods, R.6
Forst, T.7
Beyer, J.8
Steiner, S.S.9
-
36
-
-
77955903375
-
Technosphere insulin: Defining the role of Technosphere particles at the cellular level
-
Angelo R, Rousseau K, Grant M, Leone-Bay A, and Ri-chardson P: Technosphere insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol. 2009;3:545-554.
-
(2009)
J Diabetes Sci Technol
, vol.3
, pp. 545-554
-
-
Angelo, R.1
Rousseau, K.2
Grant, M.3
Leone-Bay, A.4
Ri-Chardson, P.5
-
38
-
-
17444378903
-
Dry powder for pulmonary delivery of peptides and proteins
-
Okamoto H, Todo H, Iida K, and Danjo K: Dry powder for pulmonary delivery of peptides and proteins. Kona. 2002;20:71-83.
-
(2002)
Kona
, vol.20
, pp. 71-83
-
-
Okamoto, H.1
Todo, H.2
Iida, K.3
Danjo, K.4
-
39
-
-
33750700160
-
Transport of aerosolized IL-2 chimeric protein using polymeric immu-noglobulin receptor in the lung
-
RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
-
Sacaan AI, Edwards WR, Domingo D, et al.: Transport of aerosolized IL-2 chimeric protein using polymeric immu-noglobulin receptor in the lung. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 357-360, 2004.
-
(2004)
Respiratory Drug Delivery IX
, pp. 357-360
-
-
Sacaan, A.I.1
Edwards, W.R.2
Domingo, D.3
-
40
-
-
25844519559
-
Antibody trans-porters\are they usable carriers for biopharmaceuticals?
-
RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr (eds) Amy Davis Biggs, River Grove, IL
-
Bitonti A, Dumont J, Garcia AM, et al.: Antibody trans-porters\are they usable carriers for biopharmaceuticals? In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 79-85, 2004.
-
(2004)
Respiratory Drug Delivery IX
, pp. 79-85
-
-
Bitonti, A.1
Dumont, J.2
Garcia, A.M.3
-
41
-
-
3042795848
-
Pulmonary delivery of erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway
-
Bitonti A, Dumont J, Low S, Peters RT, Kropp KE, Pa-lombella VT, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, and Blumberget RS: Pulmonary delivery of erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA. 2004;101: 9763-9768.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 9763-9768
-
-
Bitonti, A.1
Dumont, J.2
Low, S.3
Peters, R.T.4
Kropp, K.E.5
Pa-Lombella, V.T.6
Stattel, J.M.7
Lu, Y.8
Tan, C.A.9
Song, J.J.10
Garcia, A.M.11
Simister, N.E.12
Spiekermann, G.M.13
Lencer, W.I.14
Blumberget, R.S.15
-
42
-
-
21744451528
-
Modifying the pul-monary absorption and retention of proteins through PE-Gylation
-
RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr (eds) Amy Davis Biggs, River Grove, IL
-
Leach CI, Kuo M-C, Bueche B, et al.: Modifying the pul-monary absorption and retention of proteins through PE-Gylation. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 69-77, 2004.
-
(2004)
Respiratory Drug Delivery IX
, pp. 69-77
-
-
Leach, C.I.1
Kuo, M.-C.2
Bueche, B.3
-
43
-
-
0023131314
-
Comparison of physical and inhalation properties of spray-dried and me-chanically micronized sodium cromoglycate
-
Vidgren MT, Vidgren PA, and Panonen TP: Comparison of physical and inhalation properties of spray-dried and me-chanically micronized sodium cromoglycate. Int J Pharm. 1987; 35:139-144.
-
(1987)
Int J Pharm
, vol.35
, pp. 139-144
-
-
Vidgren, M.T.1
Vidgren, P.A.2
Panonen, T.P.3
-
44
-
-
0031393964
-
The effect of operating and formulation variables on the mor-phology of spray-dried protein particles
-
Maa YF, Constantino HR, Nguyen PA, and Hsu CC: The effect of operating and formulation variables on the mor-phology of spray-dried protein particles. Pharm Dev Technol. 1997;2:213-223.
-
(1997)
Pharm Dev Technol
, vol.2
, pp. 213-223
-
-
Maa, Y.F.1
Constantino, H.R.2
Nguyen, P.A.3
Hsu, C.C.4
-
45
-
-
42049094490
-
Pharmaceutical particle engineering via spray-drying
-
Vehring R: Pharmaceutical particle engineering via spray-drying. Pharm Res. 2008;25:999-1022.
-
(2008)
Pharm Res
, vol.25
, pp. 999-1022
-
-
Vehring, R.1
-
47
-
-
42049100251
-
Embedded crystals in low density particles: Formulation, manufacture, and properties
-
RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
-
Tarara T, Malcolmson R, Leung D, and Weers J: Embedded crystals in low density particles: formulation, manufacture, and properties. In RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery X. Amy Davis Biggs, River Grove, IL; pp. 297-304, 2006.
-
(2006)
Respiratory Drug Delivery X
, pp. 297-304
-
-
Tarara, T.1
Malcolmson, R.2
Leung, D.3
Weers, J.4
-
49
-
-
33750804217
-
Particle engineering tech-niques for inhaled biopharmaceuticals
-
Shoyele SA, and Cawthorne S: Particle engineering tech-niques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009-1029.
-
(2006)
Adv Drug Deliv Rev
, vol.58
, pp. 1009-1029
-
-
Shoyele, S.A.1
Cawthorne, S.2
-
50
-
-
33646896501
-
Formulation and charac-terization of lipid-coated tobramycin particles for dry powder inhalation
-
Pilcer G, Sebti T, and Amighi K: Formulation and charac-terization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res. 2006;23:931-940.
-
(2006)
Pharm Res
, vol.23
, pp. 931-940
-
-
Pilcer, G.1
Sebti, T.2
Amighi, K.3
-
51
-
-
2442666256
-
A novel spray-drying technique to produce low density particles for pulmonary delivery
-
Steckl H, and Brandes HG: A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm. 2004;278:187-195.
-
(2004)
Int J Pharm
, vol.278
, pp. 187-195
-
-
Steckl, H.1
Brandes, H.G.2
-
52
-
-
0037126053
-
Trojan particles: Large porous carriers of nanoparticles for drug delivery
-
Tsapis N, Bennett D, Jackson B, Weitz DA, and Edwards DA: Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA. 2002;99:12001-12005.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 12001-12005
-
-
Tsapis, N.1
Bennett, D.2
Jackson, B.3
Weitz, D.A.4
Edwards, D.A.5
-
55
-
-
33947287573
-
Drying-induced variations in physicochemical properties of amorphous pharmaceuti-cals and their impact on stability (I): Stability of a mono-clonal antibody
-
Abdul-Fattah AM, Truong-Le V, Yee L, Nguyen L, Kalonia DS, Cicerone MT, and Pikal MJ: Drying-induced variations in physicochemical properties of amorphous pharmaceuti-cals and their impact on stability (I): stability of a mono-clonal antibody. J Pharm Sci. 2007;96:1983-2008.
-
(2007)
J Pharm Sci
, vol.96
, pp. 1983-2008
-
-
Abdul-Fattah, A.M.1
Truong-Le, V.2
Yee, L.3
Nguyen, L.4
Kalonia, D.S.5
Cicerone, M.T.6
Pikal, M.J.7
-
56
-
-
0000425854
-
Particle engineering by supercritical fluid technologies for powder inhalation drug delivery
-
PR Byron, RN Dalby, and SJ Farr (eds) Interpharm Press, Buffalo Grove, IL
-
York P, and Hanna M: Particle engineering by supercritical fluid technologies for powder inhalation drug delivery. In: PR Byron, RN Dalby, and SJ Farr (eds). Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL; pp. 231-239, 1996.
-
(1996)
Respiratory Drug Delivery v
, pp. 231-239
-
-
York, P.1
Hanna, M.2
-
57
-
-
0033365877
-
Formation of small droplet aerosols assisted by supercritical carbon dioxide
-
Sievers RE, Karst U, Milewski PD, et al.: Formation of small droplet aerosols assisted by supercritical carbon dioxide. Aerosol Sci Technol. 1999;30:3-15.
-
(1999)
Aerosol Sci Technol
, vol.30
, pp. 3-15
-
-
Sievers, R.E.1
Karst, U.2
Milewski, P.D.3
-
58
-
-
70449088928
-
Engineering of crystalline combination inhalation particles of a long-acting beta-2 agonist and a corticosteroid
-
Pitchayajittipong C, Shur J, and Price R: Engineering of crystalline combination inhalation particles of a long-acting beta-2 agonist and a corticosteroid. Pharm Res. 2009;26: 2657-2666.
-
(2009)
Pharm Res
, vol.26
, pp. 2657-2666
-
-
Pitchayajittipong, C.1
Shur, J.2
Price, R.3
-
59
-
-
39749100131
-
Preparation of inhalable salbutamol sulfate using reactive high gravity controlled precipitation
-
Hu TT, Chiou H, Chan H-K, Chen J-F, and Yun J: Preparation of inhalable salbutamol sulfate using reactive high gravity controlled precipitation. J Pharm Sci. 2008;97:944-949.
-
(2008)
J Pharm Sci
, vol.97
, pp. 944-949
-
-
Hu, T.T.1
Chiou, H.2
Chan, H.-K.3
Chen, J.-F.4
Yun, J.5
-
60
-
-
43649096146
-
A novel production method for inhalable cyclosporin A powders by confined liquid impinging jet precipitation
-
Chiou H, Chan H-K, Heng D, Prud'Homme RK, and Raper JA: A novel production method for inhalable cyclosporin A powders by confined liquid impinging jet precipitation. J Aerosol Sci. 2008;39:500-509.
-
(2008)
J Aerosol Sci
, vol.39
, pp. 500-509
-
-
Chiou, H.1
Chan, H.-K.2
Heng, D.3
Prud'Homme, R.K.4
Raper, J.A.5
-
61
-
-
0038826781
-
Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volun-teers
-
Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, and Weers JG.: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volun-teers. Chest. 2003;124:360-366.
-
(2003)
Chest
, vol.124
, pp. 360-366
-
-
Newhouse, M.T.1
Hirst, P.H.2
Duddu, S.P.3
Walter, Y.H.4
Tarara, T.E.5
Clark, A.R.6
Weers, J.G.7
-
62
-
-
33746480274
-
Pharmacoscintigraphic eval-uation of lipid dry powder budesonide formulations for inhalation
-
Sebti T, Pilcer G, Van Gansbeke B, Goldman S, Michils A, Vanderbist F, and Amighi K: Pharmacoscintigraphic eval-uation of lipid dry powder budesonide formulations for inhalation. Eur J Pharm Biopharm. 2006;64:26-32.
-
(2006)
Eur J Pharm Biopharm
, vol.64
, pp. 26-32
-
-
Sebti, T.1
Pilcer, G.2
Van Gansbeke, B.3
Goldman, S.4
Michils, A.5
Vanderbist, F.6
Amighi, K.7
-
63
-
-
37849042758
-
Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formula-tions in cystic fibrosis patients
-
Pilcer G, Goole J, van Gansbeke B, Blocklet D, Knoop C, Vanderbrist F, and Amighi K: Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formula-tions in cystic fibrosis patients. Eur J Pharm Biopharm. 2008;68:413-421.
-
(2008)
Eur J Pharm Biopharm
, vol.68
, pp. 413-421
-
-
Pilcer, G.1
Goole, J.2
Van Gansbeke, B.3
Blocklet, D.4
Knoop, C.5
Vanderbrist, F.6
Amighi, K.7
-
64
-
-
33645413962
-
High dose inhaled powder delivery-challenges and techniques
-
RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
-
Weers J, Clark A, and Challoner P: High dose inhaled powder delivery-challenges and techniques. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 357-360, 2004.
-
(2004)
Respiratory Drug Delivery IX
, pp. 357-360
-
-
Weers, J.1
Clark, A.2
Challoner, P.3
-
65
-
-
34247193128
-
Novel tobramycin inhalation powder in cystic fi-brosis subjects: Pharmacokinetics and safety
-
Geller DE, Konstan MW, Smith J, Noonberg SB, and Con-rad C: Novel tobramycin inhalation powder in cystic fi-brosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42:307-313.
-
(2007)
Pediatr Pulmonol
, vol.42
, pp. 307-313
-
-
De, G.1
Konstan, M.W.2
Smith, J.3
Noonberg, S.B.4
Con-Rad, C.5
-
66
-
-
33847777944
-
Dry powder inhalation versus wet nebulization delivery of antibiotics in cystic fibrosis patients
-
Westerman EM, Heijerman HG, and Frijlink HW: Dry powder inhalation versus wet nebulization delivery of antibiotics in cystic fibrosis patients. Exp Opin Drug Del. 2007;4:91-94.
-
(2007)
Exp Opin Drug Del
, vol.4
, pp. 91-94
-
-
Westerman, E.M.1
Heijerman, H.G.2
Frijlink, H.W.3
-
67
-
-
70350228508
-
Inhaled drug delivery for tuberculosis therapy
-
Muttil P, Wang C, and Hickey AJ: Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26:2401-2416.
-
(2009)
Pharm Res
, vol.26
, pp. 2401-2416
-
-
Muttil, P.1
Wang, C.2
Hickey, A.J.3
-
70
-
-
33748691353
-
In-situ coating: An approach for particle modification and encapsulation of proteins during spray-drying
-
Elversson J, and Millqvist-Fureby A: In-situ coating: an approach for particle modification and encapsulation of proteins during spray-drying. Int J Pharm 2006;323:52-63.
-
(2006)
Int J Pharm
, vol.323
, pp. 52-63
-
-
Elversson, J.1
Millqvist-Fureby, A.2
-
71
-
-
33846076698
-
Degree of throat deposition can explain the variability in lung deposition of inhaled drugs
-
Börgstrom L, Olsson B, and Thorsson L: Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473-483.
-
(2006)
J Aerosol Med
, vol.19
, pp. 473-483
-
-
Börgstrom, L.1
Olsson, B.2
Thorsson, L.3
-
73
-
-
78650192172
-
Effects of device design on patient compliance: Comparing the same drug in different devices. in
-
RN Dalby, PR Byron, J Peart, and JD Suman (eds) Davis Healthcare, River Grove, IL
-
Chrystyn H: Effects of device design on patient compliance: comparing the same drug in different devices. In: RN Dalby, PR Byron, J Peart, and JD Suman (eds). Respiratory Drug Delivery Europe 2009. Davis Healthcare, River Grove, IL; pp. 105-116, 2009.
-
Respiratory Drug Delivery Europe 2009
, vol.2009
, pp. 105-116
-
-
Chrystyn, H.1
-
74
-
-
0034864138
-
Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity
-
Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, and Witnek TJ: Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14:309-315.
-
(2001)
J Aerosol Med
, vol.14
, pp. 309-315
-
-
Chodosh, S.1
Flanders, J.S.2
Kesten, S.3
Serby, C.W.4
Hochrainer, D.5
Witnek, T.J.6
-
75
-
-
77955421503
-
Concept 1 (a single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients
-
RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds) Davis Healthcare, River Grove, IL
-
Pavkov R, Singh D, and Reitveld I: Concept 1 (a single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2008. Davis Healthcare, River Grove, IL; pp. 683-686, 2008.
-
Respiratory Drug Delivery 2008
, vol.2008
, pp. 683-686
-
-
Pavkov, R.1
Singh, D.2
Reitveld, I.3
-
76
-
-
78650224939
-
Beyond the throat: Preferred methods of asses-sing regional distribution in the lung
-
RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds) Davis Healthcare Interna-tional Publishing, River Grove, IL
-
Clark AR: Beyond the throat: Preferred methods of asses-sing regional distribution in the lung. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2010. Davis Healthcare Interna-tional Publishing, River Grove, IL; pp. 235-244, 2010.
-
(2010)
Respiratory Drug Delivery 2010
, pp. 235-244
-
-
Clark, A.R.1
-
77
-
-
0027937427
-
The new ICRP model for the respiratory tract
-
Bailey MR: The new ICRP model for the respiratory tract. Radiat Protein Dosim. 1994;53:107-114.
-
(1994)
Radiat Protein Dosim
, vol.53
, pp. 107-114
-
-
Bailey, M.R.1
-
80
-
-
1142309474
-
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controlled therapies
-
Stoloff SW, Stempel DA, Meyer T, Stanford RH, and Car-ranza Rosenzweig JR: Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controlled therapies. J Allergy Clin Immunol. 2004;113:245-251.
-
(2004)
J Allergy Clin Immunol
, vol.113
, pp. 245-251
-
-
Stoloff, S.W.1
Stempel, D.A.2
Meyer, T.3
Stanford, R.H.4
Car-Ranza Rosenzweig, J.R.5
-
81
-
-
0037999825
-
Enhanced synergy between fluticasone pro-pionate and salmeterol inhaled from a single inhaler versus separate inhalers
-
Nelson HS, Chapman KR, Pyke SD, Johnson M, and Pritchard JN: Enhanced synergy between fluticasone pro-pionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112:29-36.
-
(2003)
J Allergy Clin Immunol
, vol.112
, pp. 29-36
-
-
Nelson, H.S.1
Chapman, K.R.2
Pyke, S.D.3
Johnson, M.4
Pritchard, J.N.5
-
82
-
-
14744303633
-
Combination therapy of long-acting beta ago-nists and inhaled corticosteroids in the management of chronic asthma
-
Nelson HS: Combination therapy of long-acting beta ago-nists and inhaled corticosteroids in the management of chronic asthma. Curr Allergy Asthma Rep. 2005;5:123-129.
-
(2005)
Curr Allergy Asthma Rep
, vol.5
, pp. 123-129
-
-
Nelson, H.S.1
-
83
-
-
33846564005
-
Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?
-
Sin DD, and Man SFP: Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? Curr Opin Pulmon Med. 2007;13:90-97.
-
(2007)
Curr Opin Pulmon Med
, vol.13
, pp. 90-97
-
-
Sin, D.D.1
Sfp, M.2
-
84
-
-
33845418508
-
Asthma related ED/hospitalization risk and asthma costs of fluticasone propi-onate/salmeterol in a single inhaler compared to flutica-sone propionate and salmeterol in separate inhalers
-
Stempel DA, Stanford RH, and Kim T: Asthma related ED/hospitalization risk and asthma costs of fluticasone propi-onate/salmeterol in a single inhaler compared to flutica-sone propionate and salmeterol in separate inhalers. J Allergy Clin Immunol. 2004;113(Suppl):S272.
-
(2004)
J Allergy Clin Immunol
, vol.113
, Issue.SUPPL.
-
-
Stempel, D.A.1
Stanford, R.H.2
Kim, T.3
-
85
-
-
0036153433
-
Scientific rationale for inhaled combination therapy with long-acting beta(2)-agonists and corticoste-roids
-
Barnes PJ: Scientific rationale for inhaled combination therapy with long-acting beta(2)-agonists and corticoste-roids. Eur Respir J. 2002;19:182-191.
-
(2002)
Eur Respir J
, vol.19
, pp. 182-191
-
-
Barnes, P.J.1
-
86
-
-
77951205795
-
Overcoming the challenges of developing combination products in different inhalation device platforms
-
Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, and Young PM (eds) Davis Healthcare Intl Publ, River Grove, IL
-
Hannay M, Govind N, Ludzik A, Jansen R, and Fletcher I: Overcoming the challenges of developing combination products in different inhalation device platforms. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, and Young PM (eds). Respiratory Drug Delivery 2008. Davis Healthcare Intl Publ, River Grove, IL; pp. 319-328, 2008.
-
Respiratory Drug Delivery 2008
, vol.2008
, pp. 319-328
-
-
Hannay, M.1
Govind, N.2
Ludzik, A.3
Jansen, R.4
Fletcher, I.5
-
87
-
-
78650197961
-
An assess-ment of the in vitro deposition of aerosolized drugs from a combination dry powder inhaler using the Andersen cascade impactor (ACI)
-
RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Davis Healthcare, River Grove, IL
-
Taki M, Zeng XM, Marriott C, and Martin G: An assess-ment of the in vitro deposition of aerosolized drugs from a combination dry powder inhaler using the Andersen cascade impactor (ACI). In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery 2006. Davis Healthcare, River Grove, IL; pp. 655-657, 2006.
-
Respiratory Drug Delivery 2006
, vol.2006
, pp. 655-657
-
-
Taki, M.1
Zeng, X.M.2
Marriott, C.3
Martin, G.4
-
88
-
-
0031001329
-
Variations in the adhesion force between a drug and carrier particles as a result of changes in the relative humidity of the air
-
Podezcek F, Newton JM, and James MB: Variations in the adhesion force between a drug and carrier particles as a result of changes in the relative humidity of the air. Int J Pharm. 1997;149:151-160.
-
(1997)
Int J Pharm
, vol.149
, pp. 151-160
-
-
Podezcek, F.1
Newton, J.M.2
James, M.B.3
-
89
-
-
33644617924
-
Dry powder inhaler formula-tions
-
Telko MJ, and Hickey AJ: Dry powder inhaler formula-tions. Respir Care. 2005;9:1209-1220.
-
(2005)
Respir Care
, vol.9
, pp. 1209-1220
-
-
Telko, M.J.1
Hickey, A.J.2
-
90
-
-
78650205640
-
Unit dose level particle size distribution characterization of combi-nation drug inhalation product
-
RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Davis Healthcare, River Grove, IL
-
Menzeleev R, Derrien Y, Bovet J, and Hickey AJ: Unit dose level particle size distribution characterization of combi-nation drug inhalation product. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery 2006, Davis Healthcare, River Grove, IL; pp. 585-588, 2006.
-
Respiratory Drug Delivery 2006
, vol.2006
, pp. 585-588
-
-
Menzeleev, R.1
Derrien, Y.2
Bovet, J.3
Hickey, A.J.4
-
91
-
-
78650217670
-
Production-scale optimization of the manufacturing process for HFA-134a metered dose inhaler containing both salmeterol (SAL) and fluticasone propionate (FP)
-
Duquemin SJ, Ashurst IC, Burke AL, et al.: Production-scale optimization of the manufacturing process for HFA-134a metered dose inhaler containing both salmeterol (SAL) and fluticasone propionate (FP). Proceedings from Drug Delivery to the Lungs VIII, 1997.
-
(1997)
Proceedings from Drug Delivery to the Lungs VIII
-
-
Duquemin, S.J.1
Ashurst, I.C.2
Burke, A.L.3
-
93
-
-
0035912936
-
Char-acterization of the aggregation behavior in a salmeterol and fluticasone propionate inhalation aerosol system
-
Snowden MY, Chowdhry BZ, Ashurst IC, et al,: Char-acterization of the aggregation behavior in a salmeterol and fluticasone propionate inhalation aerosol system. Int J Pharm. 2001;221:165-174.
-
(2001)
Int J Pharm
, vol.221
, pp. 165-174
-
-
Snowden, M.Y.1
Chowdhry, B.Z.2
Ashurst, I.C.3
-
94
-
-
70449129733
-
The influence of flow rate on the aerosol deposition profile and electro-static charge of single and combination metered dose in-halers
-
Hoe S, Traini D, Chan H-K, and Young PM: The influence of flow rate on the aerosol deposition profile and electro-static charge of single and combination metered dose in-halers. Pharm Res. 2009;26:2639-2646.
-
(2009)
Pharm Res
, vol.26
, pp. 2639-2646
-
-
Hoe, S.1
Traini, D.2
Chan, H.-K.3
Young, P.M.4
-
98
-
-
84868140484
-
Co-deposition of albuterol sulfate, ipratropium bromide co-crystal aerosols
-
RN Dalby, PR Byron, J Peart, and JD Suman (eds) Davis Healthcare, River Grove, IL
-
Jin F, Hindle M, and Byron P: Co-deposition of albuterol sulfate, ipratropium bromide co-crystal aerosols. In: RN Dalby, PR Byron, J Peart, and JD Suman (eds). Respiratory Drug Delivery Europe 2007. Davis Healthcare, River Grove, IL; pp. 373-376, 2007.
-
Respiratory Drug Delivery Europe 2007
, vol.2007
, pp. 373-376
-
-
Jin, F.1
Hindle, M.2
Byron, P.3
-
100
-
-
78650210506
-
-
US Patent 7, 267, 813
-
Watanabe W, Kauppinen, Ahomen P, Brown D, and Mut-tonen E: Inhalation particles incorporating a combination of two or more active agents. US Patent 7,267,813; 2007.
-
(2007)
Inhalation Particles Incorporating A Combination of Two or More Active Agents
-
-
Watanabe, W.1
Kauppinen Ahomen, P.2
Brown, D.3
Mut-Tonen, E.4
-
101
-
-
67349131897
-
Combination chemothera-peutic dry powder aerosols via controlled nanoparticle agglomeration
-
El-Gendy N, and Berkland C: Combination chemothera-peutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009;26:1752-1763.
-
(2009)
Pharm Res
, vol.26
, pp. 1752-1763
-
-
El-Gendy, N.1
Berkland, C.2
-
102
-
-
49249105173
-
Combination particles con-taining salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment
-
Westmeier R, and Steckel H: Combination particles con-taining salmeterol xinafoate and fluticasone propionate: formulation and aerodynamic assessment. J Pharm Sci. 2008; 97:2299-2310.
-
(2008)
J Pharm Sci
, vol.97
, pp. 2299-2310
-
-
Westmeier, R.1
Steckel, H.2
-
103
-
-
33748306274
-
Physicochem-ical and in vitro deposition properties of salbutamol sul-phate/impratropium bromide and salbutamol sulphate/excipient spray-dried mixtures for use in dry powder in-halers
-
Corrigan DO, Corrigan OI, and Healy AM: Physicochem-ical and in vitro deposition properties of salbutamol sul-phate/impratropium bromide and salbutamol sulphate/excipient spray-dried mixtures for use in dry powder in-halers. Int J Pharm. 2006;322:22-30.
-
(2006)
Int J Pharm
, vol.322
, pp. 22-30
-
-
Corrigan, D.O.1
Corrigan, O.I.2
Healy, A.M.3
-
104
-
-
52449086630
-
Co-spray dried antibiotics for dry powder lung delivery
-
Adi H, Young PM, Chan HK, Stewart P, Agus H, and Traini D: Co-spray dried antibiotics for dry powder lung delivery. J Pharm Sci. 2008; 97:3356-3366.
-
(2008)
J Pharm Sci
, vol.97
, pp. 3356-3366
-
-
Adi, H.1
Young, P.M.2
Chan, H.K.3
Stewart, P.4
Agus, H.5
Traini, D.6
-
105
-
-
53849117442
-
Microparticles for inhalational delivery of antipseudomonal antibiotics
-
Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, and Kohane DS: Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J. 2008;10:254-260.
-
(2008)
AAPS J
, vol.10
, pp. 254-260
-
-
Tsifansky, M.D.1
Yeo, Y.2
Evgenov, O.V.3
Bellas, E.4
Benjamin, J.5
Kohane, D.S.6
-
106
-
-
58249116658
-
Spray drying of budesonide, formoterol fumarate and their composites\1. Physicochemical characterization
-
Tajber L, Corrigan DO, Corrigan OI, and Healy AM: Spray drying of budesonide, formoterol fumarate and their composites\1. Physicochemical characterization. Int J Pharm. 2009;367:79-85.
-
(2009)
Int J Pharm
, vol.367
, pp. 79-85
-
-
Tajber, L.1
Corrigan, D.O.2
Corrigan, O.I.3
Healy, A.M.4
-
107
-
-
58249113923
-
Spray drying of budesonide, formoterol fumarate and their composites II. Statistical factorial design and in vitro deposition proper-ties
-
Tajber L, Corrigan OI, and Healy AM: Spray drying of budesonide, formoterol fumarate and their composites II. Statistical factorial design and in vitro deposition proper-ties. Int J Pharm. 2009;367:86-96.
-
(2009)
Int J Pharm
, vol.367
, pp. 86-96
-
-
Tajber, L.1
Corrigan, O.I.2
Healy, A.M.3
-
108
-
-
64149102365
-
Sustained delivery by leucine-modifed chitosan spray-dried respira-ble powders
-
Learoyd TP, Burrows JL, French E, and Seville P: Sustained delivery by leucine-modifed chitosan spray-dried respira-ble powders. Int J Pharm. 2009; 372:97-104.
-
(2009)
Int J Pharm
, vol.372
, pp. 97-104
-
-
Learoyd, T.P.1
Burrows, J.L.2
French, E.3
Seville, P.4
-
109
-
-
72949104558
-
Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and cipro-floxacin for treatment of cystic fibrosis
-
Yang Y, Tsifansky MD, Wu C-J, Yang HI, Schmidt G, and Yeo Y: Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and cipro-floxacin for treatment of cystic fibrosis. Pharm Res. 2010; 27:151-160
-
(2010)
Pharm Res.
, vol.27
, pp. 151-160
-
-
Yang, Y.1
Tsifansky, M.D.2
Wu, C.-J.3
Yang, H.I.4
Schmidt, G.5
Yeo, Y.6
-
110
-
-
77951207948
-
Can low-dose combination products for inhalation be formu-lated in single crystalline particles?
-
Kumon M, Kwok PCL, Adi H, Heng D, and Chan H-K: Can low-dose combination products for inhalation be formu-lated in single crystalline particles? Eur J Pharm Sci. 2010; 40:16-24.
-
(2010)
Eur J Pharm Sci.
, vol.40
, pp. 16-24
-
-
Kumon, M.1
Pcl, K.2
Adi, H.3
Heng, D.4
Chan, H.-K.5
-
112
-
-
0015425028
-
Absorption of drugs from the rat lung
-
Enna SJ, and Schanker LS: Absorption of drugs from the rat lung. Am J Physiol. 1972;223:1227-1231.
-
(1972)
Am J Physiol
, vol.223
, pp. 1227-1231
-
-
Enna, S.J.1
Schanker, L.S.2
-
113
-
-
26944439522
-
The lungs as a portal of entry for systemic drug delivery
-
Patton JS, Fishburn CS, and Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thor Soc. 2004;1:338-344.
-
(2004)
Proc Am Thor Soc
, vol.1
, pp. 338-344
-
-
Patton, J.S.1
Fishburn, C.S.2
Weers, J.G.3
-
115
-
-
0027984419
-
Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae Staphylococcus aureus and Pseudomonas aeruginosa for which MICs are similar
-
Hyatt JM, Nix DE, and Schentag JJ: Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Anti-microb Agents Chemother. 1994;38:2730-2737.
-
(1994)
Antimicrob Agents Chemother
, vol.38
, pp. 2730-2737
-
-
Hyatt, J.M.1
De, N.2
Schentag, J.J.3
-
116
-
-
1642313902
-
Liposome delivery of ciprofloxacin against intracellular Francisella tularensis in-fection
-
Wong JP, Yang H, and Blasetti KL: Liposome delivery of ciprofloxacin against intracellular Francisella tularensis in-fection. J Control Rel. 2003; 92:265-273.
-
(2003)
J Control Rel
, vol.92
, pp. 265-273
-
-
Wong, J.P.1
Yang, H.2
Blasetti, K.L.3
-
117
-
-
78650209506
-
-
US Patent Application 2004/0254194 A1
-
Endermann R, Labischinski H, Ladel C, Petersen U, and Newton B: Treatment of bacterial diseases of the respiratory organs. US Patent Application, 2004/0254194 A1; 2004.
-
Treatment of Bacterial Diseases of the Respiratory Organs
, vol.2004
-
-
Endermann, R.1
Labischinski, H.2
Ladel, C.3
Petersen, U.4
Newton, B.5
-
119
-
-
84881514244
-
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis patients
-
Brest, France, Poster #196
-
Bruinenberg P, Otulana B, Blanchard J, Cipolla D, Wilson J, and Serisier D: Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis patients. Presented at the 32nd European Cystic Fibrosis Conference, Brest, France, Poster #196; 2009.
-
(2009)
Presented at the 32nd European Cystic Fibrosis Conference
-
-
Bruinenberg, P.1
Otulana, B.2
Blanchard, J.3
Cipolla, D.4
Wilson, J.5
Serisier, D.6
-
120
-
-
0027979363
-
Formulation and in-vitro performance of liposome powder aerosols
-
Schreier H, Mobley WC, Concessio N, Hickey AJ, and Ni-ven RW: Formulation and in-vitro performance of liposome powder aerosols. STP Pharma Sci. 1994;4:38-44.
-
(1994)
STP Pharma Sci
, vol.4
, pp. 38-44
-
-
Schreier, H.1
Mobley, W.C.2
Concessio, N.3
Hickey, A.J.4
Ni-Ven, R.W.5
-
121
-
-
0022456536
-
Preparation, characterization, and controlled release from coprecipitates of fluorescein and magnesium hydroxide
-
Hickey AJ, and Byron PR: Preparation, characterization, and controlled release from coprecipitates of fluorescein and magnesium hydroxide. J Pharm Sci. 1986; 75:756-759.
-
(1986)
J Pharm Sci
, vol.75
, pp. 756-759
-
-
Hickey, A.J.1
Byron, P.R.2
-
122
-
-
0033795452
-
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization
-
O'Hara P, and Hickey AJ: Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000;17: 955-961.
-
(2000)
Pharm Res
, vol.17
, pp. 955-961
-
-
O'Hara, P.1
Hickey, A.J.2
-
123
-
-
78650193027
-
Inhaled liposomal cipro-floxacin: In vitro properties and aerosol performance
-
RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds) Davis Healthcare Intl Publishing LLC, River Grove, IL
-
Cipolla DC, Dayton F, Fulzele S, Gabatan E, Mudumba S, Yim D, Wu H, and Zwolinski R. Inhaled liposomal cipro-floxacin: in vitro properties and aerosol performance. In RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2010. Davis Healthcare Intl Publishing LLC, River Grove, IL; pp. 409-414, 2010.
-
(2010)
Respiratory Drug Delivery 2010
, pp. 409-414
-
-
Cipolla, D.C.1
Dayton, F.2
Fulzele, S.3
Gabatan, E.4
Mudumba, S.5
Yim, D.6
Wu, H.7
Zwolinski, R.8
-
124
-
-
78650214408
-
Mu-dumbaS, and GondaI. Inhaled liposomal ciprofloxacin: Once a day management ofrespiratory infections
-
RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds) Davis Healthcare Intl Publishing LLC, River Grove, IL
-
Bruinenberg P, Blanchard JD, Cipolla DC, Dayton F, Mu-dumbaS, and GondaI. Inhaled liposomal ciprofloxacin: once a day management ofrespiratory infections. In RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Re-spiratory Drug Delivery 2010. Davis Healthcare Intl Publishing LLC, River Grove, IL; pp. 73-81, 2010.
-
(2010)
Re-spiratory Drug Delivery 2010
, pp. 73-81
-
-
Bruinenberg, P.1
Blanchard, J.D.2
Cipolla, D.C.3
Dayton, F.4
-
125
-
-
41149105955
-
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudo-monas aeruginosa lung infections
-
Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, and Per-kins WR: Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudo-monas aeruginosa lung infections. J Antimicrob Chemother. 2008;61:859-868.
-
(2008)
J Antimicrob Chemother
, vol.61
, pp. 859-868
-
-
Meers, P.1
Neville, M.2
Malinin, V.3
Scotto, A.W.4
Sardaryan, G.5
Kurumunda, R.6
MacKinson, C.7
James, G.8
Fisher, S.9
Per-Kins, W.R.10
-
126
-
-
54949136128
-
Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size
-
Zhang LZ, Wurtz W, Lee JK, Malinin V, Durwas-Krishnan S, Meers P, and Perkins WR: Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulmon Drug Del. 2008;21:245-254.
-
(2008)
J Aerosol Med Pulmon Drug Del
, vol.21
, pp. 245-254
-
-
Zhang, L.Z.1
Wurtz, W.2
Lee, J.K.3
Malinin, V.4
Durwas-Krishnan, S.5
Meers, P.6
Perkins, W.R.7
-
127
-
-
34247897230
-
Phase 1 study of aerosolized SLIT Cisplatin in the treatment of patients with carcinoma of the lung
-
Wittgen BPH, Kunst PWA, Van der Born K, Van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicholson S, Pe-ters G, and Postmus PE: Phase 1 study of aerosolized SLIT Cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res. 2007;13:2414-2421.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2414-2421
-
-
Bph, W.1
Pwa, K.2
Van Der Born, K.3
Van Wijk, A.W.4
Perkins, W.5
Pilkiewicz, F.G.6
Perez-Soler, R.7
Nicholson, S.8
Pe-Ters, G.9
Postmus, P.E.10
-
128
-
-
0032587355
-
Anticancer effect of 9-camptothecin liposome aerosol on human cancer xenografts in nude mice
-
Knight V, Koshkina NV, Waldrep JC, Giovanella BC, and Gilbert BC: Anticancer effect of 9-camptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol. 1999;44:177-186.
-
(1999)
Cancer Chemother Pharmacol
, vol.44
, pp. 177-186
-
-
Knight, V.1
Koshkina, N.V.2
Waldrep, J.C.3
Giovanella, B.C.4
Gilbert, B.C.5
-
129
-
-
64749110689
-
Recent advances in liposomal dry powder formulations: Preparation and evaluation
-
Misra A, Jinturkar K, Patel D, Lalani J, and Chougule M: Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opin Drug Deliv. 2009;6:71-89.
-
(2009)
Expert Opin Drug Deliv
, vol.6
, pp. 71-89
-
-
Misra, A.1
Jinturkar, K.2
Patel, D.3
Lalani, J.4
Chougule, M.5
-
130
-
-
67650093219
-
Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery
-
Sung JC, Padilla DJ, Garcia-Contreras L, VerBerkmoes JL, Durbin D, Peloquin CA, Elbert KJ, Hickey AJ, and Edwards DA: Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26:1847-1855.
-
(2009)
Pharm Res
, vol.26
, pp. 1847-1855
-
-
Sung, J.C.1
Padilla, D.J.2
Garcia-Contreras, L.3
Verberkmoes, J.L.4
Durbin, D.5
Peloquin, C.A.6
Elbert, K.J.7
Hickey, A.J.8
Edwards, D.A.9
-
131
-
-
0034812708
-
Airways delivery of rifampicin microparticles for the treatment of tuberculosis
-
Suarez S, O'Hara P, Kazantseva M, Newcomer C, Hopfer R, McMurray DN, and Hickey AJ: Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48:431-434.
-
(2001)
J Antimicrob Chemother
, vol.48
, pp. 431-434
-
-
Suarez, S.1
O'Hara, P.2
Kazantseva, M.3
Newcomer, C.4
Hopfer, R.5
McMurray, D.N.6
Hickey, A.J.7
-
133
-
-
58849089005
-
Nanoparticle formulations in pulmonary drug delivery
-
Bailey MM, and Berkland CJ: Nanoparticle formulations in pulmonary drug delivery. Med Res Rev. 2009;29:196-212.
-
(2009)
Med Res Rev
, vol.29
, pp. 196-212
-
-
Bailey, M.M.1
Berkland, C.J.2
-
134
-
-
0037426696
-
Nebulization of biodegradable nanoparticles: Impact of nebulizer technology and nano-particle characteristics on aerosol features
-
Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, and Kissel T: Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nano-particle characteristics on aerosol features. J Control Release. 2003;86:131-144.
-
(2003)
J Control Release
, vol.86
, pp. 131-144
-
-
Dailey, L.A.1
Schmehl, T.2
Gessler, T.3
Wittmar, M.4
Grimminger, F.5
Seeger, W.6
Kissel, T.7
-
135
-
-
70350228508
-
Inhaled drug delivery for tuberculosis therapy
-
Muttil P, Wang C, and Hickey AJ: Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26:2401-2416.
-
(2009)
Pharm Res
, vol.26
, pp. 2401-2416
-
-
Muttil, P.1
Wang, C.2
Hickey, A.J.3
-
136
-
-
0035998946
-
Factors affecting aerosol deposition of inhaled porous drug particles
-
Musante C, Rosati J, Shroeder J, Rosati JA, Crowder TM, Hickey AJ, and Martonen TB: Factors affecting aerosol deposition of inhaled porous drug particles. J Pharm Sci. 2002;91:1590-1600.
-
(2002)
J Pharm Sci
, vol.91
, pp. 1590-1600
-
-
Musante, C.1
Rosati, J.2
Shroeder, J.3
Rosati, J.A.4
Crowder, T.M.5
Hickey, A.J.6
Martonen, T.B.7
-
137
-
-
0028407436
-
Controlled release from condensation-coated respirable aerosol parti-cles
-
Pillai RS, Yeates DB, Miller IF, and Hickey AJ: Controlled release from condensation-coated respirable aerosol parti-cles. J Aerosol Sci. 1994;25:461-477.
-
(1994)
J Aerosol Sci
, vol.25
, pp. 461-477
-
-
Pillai, R.S.1
Yeates, D.B.2
Miller, I.F.3
Hickey, A.J.4
-
138
-
-
0031913877
-
Controlled dissolution from wax-coated aerosol particles in canine lungs
-
Pillai RS, Yeates DB, Miller IF, and Hickey AJ: Controlled dissolution from wax-coated aerosol particles in canine lungs. J Applied Physiol. 1998;84:717-725.
-
(1998)
J Applied Physiol
, vol.84
, pp. 717-725
-
-
Pillai, R.S.1
Yeates, D.B.2
Miller, I.F.3
Hickey, A.J.4
-
139
-
-
33747087794
-
Manufacture, characterization, and pharmacodynamic evaluation of en-gineered ipratropium bromide particles
-
Taylor MK, Hickey AJ, and van Oort MM: Manufacture, characterization, and pharmacodynamic evaluation of en-gineered ipratropium bromide particles. Pharm Dev Tech-nol. 2006;11:321-336.
-
(2006)
Pharm Dev Tech-nol
, vol.11
, pp. 321-336
-
-
Taylor, M.K.1
Hickey, A.J.2
Van Oort, M.M.3
-
140
-
-
78650182767
-
Pharmacokinetic and pharmaco-dynamic aspectsofinhaled therapeutic
-
T Martonen (ed) WIT Press, Southampton, UK
-
Suarez S, and Hickey AJ: Pharmacokinetic and pharmaco-dynamic aspectsofinhaled therapeutic agents. In: T Martonen (ed). Medical Applications of Computer Modeling: The Respiratory System. WIT Press, Southampton, UK; pp. 225-304, 2001.
-
(2001)
Medical Applications of Computer Modeling: The Respiratory System
, pp. 225-304
-
-
Suarez, S.1
Hickey, A.J.2
-
142
-
-
14644428751
-
Inertial aerosol deposition at the surface of airway epithelial cell monolayers
-
Kazantseva M, and Hickey AJ: Inertial aerosol deposition at the surface of airway epithelial cell monolayers. Pharm Sci. 1998;1:S656.
-
(1998)
Pharm Sci
, vol.1
-
-
Kazantseva, M.1
Hickey, A.J.2
-
143
-
-
14644387257
-
Development of a lung model utilizing human alveolar epithelial cells for evaluating aerosol drug delivery
-
RN Dalby, PR Byron, J Peart, and SJ Farr (eds) Davis Horwood Publishing, Raleigh, NC
-
Kazantseva M, Cooney D, and Hickey AJ: Development of a lung model utilizing human alveolar epithelial cells for evaluating aerosol drug delivery. In: RN Dalby, PR Byron, J Peart, and SJ Farr (eds). Respiratory Drug Delivery VIII. Davis Horwood Publishing, Raleigh, NC; pp. 707-710, 2002.
-
(2002)
Respiratory Drug Delivery VIII
, pp. 707-710
-
-
Kazantseva, M.1
Cooney, D.2
Hickey, A.J.3
-
144
-
-
14644421632
-
Development of a size dependent aerosol deposition model utilizing airway epithelial cells for evaluating aerosol drug delivery
-
Cooney D, Kazantseva M, and Hickey AJ: Development of a size dependent aerosol deposition model utilizing airway epithelial cells for evaluating aerosol drug delivery. Alter-nat Lab Anim. 2004;32:581-590.
-
(2004)
Alter-nat Lab Anim
, vol.32
, pp. 581-590
-
-
Cooney, D.1
Kazantseva, M.2
Hickey, A.J.3
-
145
-
-
0345813900
-
Gene delivery to the lung
-
In AJ Hickey (ed) Marcel Dekker, New York
-
Hanes J, Dawson M, Har-el Y, Suh J, and Fiegel J: Gene delivery to the lung. In AJ Hickey (ed). Pharamceutical In-halation Aerosol Technology, 2nd ed. Marcel Dekker, New York; pp. 489-539, 2004.
-
(2004)
Pharamceutical In-halation Aerosol Technology, 2nd Ed.
, pp. 489-539
-
-
Hanes, J.1
Dawson, M.2
Har-El, Y.3
Suh, J.4
Fiegel, J.5
-
146
-
-
51049084639
-
Inhalable siRNA: Potential as a therapeutic agent in the lungs
-
Durcan N, Murphy C, and Cryan SA: Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Phar-maceut. 2008;5:559-566.
-
(2008)
Mol Phar-maceut
, vol.5
, pp. 559-566
-
-
Durcan, N.1
Murphy, C.2
Cryan, S.A.3
-
148
-
-
0000197284
-
Pancreatic extracts in the treatment of diabetes melli-tus
-
Banting FG, Best CH, Collip JB, Campbell WR, and Fletcher AA: Pancreatic extracts in the treatment of diabetes melli-tus. Can Med Assoc J. 1922; 12:141-146.
-
(1922)
Can Med Assoc J
, vol.12
, pp. 141-146
-
-
Banting, F.G.1
Ch, B.2
Collip, J.B.3
Campbell, W.R.4
Fletcher, A.A.5
-
149
-
-
77952503692
-
The failure of Exubera: Are we beating a dead horse?
-
Heinemann L: The failure of Exubera: are we beating a dead horse? J Diabetes Sci Technol 2008; 2: 518-529.
-
(2008)
J Diabetes Sci Technol
, vol.2
, pp. 518-529
-
-
Heinemann, L.1
-
150
-
-
0006619826
-
Pulmonary absorption and metabolism of peptides and proteins
-
RN Dalby, PR Byron, and SJ Farr (eds) Interpharm Press, Buffalo Grove, IL
-
Patton J, Nagarajan S, and Clark A: Pulmonary absorption and metabolism of peptides and proteins. In: RN Dalby, PR Byron, and SJ Farr (eds). Respiratory Drug Delivery VI. In-terpharm Press, Buffalo Grove, IL; pp. 17-24, 1998.
-
(1998)
Respiratory Drug Delivery VI
, pp. 17-24
-
-
Patton, J.1
Nagarajan, S.2
Clark, A.3
-
151
-
-
0026572056
-
Pulmonary delivery of peptides and proteins for systemic action
-
Patton JS, and Platz RM: Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Del Rev. 1992;8:179-228.
-
(1992)
Adv Drug Del Rev
, vol.8
, pp. 179-228
-
-
Patton, J.S.1
Platz, R.M.2
-
152
-
-
0032754797
-
Injection related anxiety in insulin-treated diabetes
-
Zambanini A: Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46:239-246.
-
(1999)
Diabetes Res Clin Pract
, vol.46
, pp. 239-246
-
-
Zambanini, A.1
-
153
-
-
0029085936
-
Needle phobia: A neglected diagnosis
-
Hamilton JG: Needle phobia: a neglected diagnosis. J Fam Pract. 1995;41:169-175.
-
(1995)
J Fam Pract
, vol.41
, pp. 169-175
-
-
Hamilton, J.G.1
-
154
-
-
13144283137
-
Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem
-
Accessed July 3 2007
-
Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, and Edelman SV: Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Clin Dia-betes. 2004;22:147-150. http://www.nektar.com/wt/page/pr- 200312/?ref/IR- archived-press-releases. Accessed July 3 2007.
-
(2004)
Clin Dia-betes
, vol.22
, pp. 147-150
-
-
Polonsky, W.H.1
Fisher, L.2
Guzman, S.3
Villa-Caballero, L.4
Edelman, S.V.5
-
155
-
-
78650221998
-
-
Stanford Graduate School of Business Case Study #OIT-80;
-
Zenios S, Chess R, and Denend L: Exubera and NICE. Stanford Graduate School of Business Case Study #OIT-80; 2008.
-
(2008)
Exubera and NICE
-
-
Zenios, S.1
Chess, R.2
Denend, L.3
-
156
-
-
36649030393
-
Inhaled insulin\gone with the wind?
-
Mathieu C, and Gale EAM: Inhaled insulin\gone with the wind? Diabetologia. 2008;51:1-5.
-
(2008)
Diabetologia
, vol.51
, pp. 1-5
-
-
Mathieu, C.1
Eam, G.2
-
157
-
-
34250749004
-
Pulmonary func-tion changes related to acute and chronic administration of inhaled insulin
-
Hegewald M, Crapo RO, and Jensen RL: Pulmonary func-tion changes related to acute and chronic administration of inhaled insulin. Diabetes Technol Therp. 2007; 9:S93-S101.
-
(2007)
Diabetes Technol Therp
, vol.9
-
-
Hegewald, M.1
Crapo, R.O.2
Jensen, R.L.3
-
158
-
-
1442275322
-
Glycemic exposure is associated with reduced pul-monary function in type 2 diabetes: The Freemantle diabetes study
-
Davis WA, Knuiman M, Kendall P, Grange V, and Davis TM: Glycemic exposure is associated with reduced pul-monary function in type 2 diabetes: the Freemantle diabetes study. Diabetes Care. 2004;27:752-757.
-
(2004)
Diabetes Care
, vol.27
, pp. 752-757
-
-
Davis, W.A.1
Knuiman, M.2
Kendall, P.3
Grange, V.4
Davis, T.M.5
-
159
-
-
33847635208
-
Disease progression modeling to characterize the effects of inhaled insulin (Exubera) on FEV1
-
French JL, Tensfeldt TG, Riese RJ, and Teeter JG: Disease progression modeling to characterize the effects of inhaled insulin (Exubera) on FEV1. Proc Am Thor Soc. 2006;3:A84.
-
(2006)
Proc Am Thor Soc
, vol.3
-
-
French, J.L.1
Tensfeldt, T.G.2
Riese, R.J.3
Teeter, J.G.4
-
160
-
-
78650192721
-
-
personal communication
-
Patton J, personal communication.
-
-
-
Patton, J.1
-
161
-
-
70349462771
-
Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: A 12 month, ran-domized noninferiority trial
-
Ang E, Lawrence MK, Heilmann CR, Ferguson JA, Tobian JA, Webb DM, and Berclaz PY: Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: a 12 month, ran-domized noninferiority trial. Diabetes Technol Ther. 2009; 11:S35-S44.
-
(2009)
Diabetes Technol Ther
, vol.11
-
-
Ang, E.1
Lawrence, M.K.2
Heilmann, C.R.3
Ferguson, J.A.4
Tobian, J.A.5
Webb, D.M.6
Berclaz, P.Y.7
-
163
-
-
78650194013
-
-
http://www.ibtimes.com/articles/20080409/pfizer-nektar-exubera-insulin. htm
-
-
-
-
164
-
-
34248192254
-
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
-
Govindarajan R, Ratnasinghe L, Simmons D, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, and Lang NP: Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007;25:1476-1481.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1476-1481
-
-
Govindarajan, R.1
Ratnasinghe, L.2
Simmons, D.3
Siegel, E.R.4
Midathada, M.V.5
Kim, L.6
Kim, P.J.7
Owens, R.J.8
Lang, N.P.9
-
165
-
-
52749089075
-
Effects of inhaled insulin on airway lining fluid composition in adults with diabetes
-
Liu MC, Riese RJ, Van Gundy K, Norwood P, Sullivan BE, Schwartz PF, and Teeter JG: Effects of inhaled insulin on airway lining fluid composition in adults with diabetes. Eur Respir J. 2008;32:180-188.
-
(2008)
Eur Respir J
, vol.32
, pp. 180-188
-
-
Liu, M.C.1
Riese, R.J.2
Van Gundy, K.3
Norwood, P.4
Sullivan, B.E.5
Schwartz, P.F.6
Teeter, J.G.7
-
166
-
-
59649124815
-
Inhaled insulin does not trigger lung inflammation and airway remodel-ing
-
Papagianni M, Hatziefthimiou A, Chachami G, Gorgou-lianis K, Molyvdas P-A, and Paraskeva E: Inhaled insulin does not trigger lung inflammation and airway remodel-ing. Eur Respir J. 2009;33:444-445.
-
(2009)
Eur Respir J
, vol.33
, pp. 444-445
-
-
Papagianni, M.1
Hatziefthimiou, A.2
Chachami, G.3
Gorgou-Lianis, K.4
Molyvdas, P.-A.5
Paraskeva, E.6
-
167
-
-
0031646537
-
Safety of inhaled proteins for therapeutic use
-
Wolff R: Safety of inhaled proteins for therapeutic use. J Aerosol Med. 1998;11:197-219.
-
(1998)
J Aerosol Med
, vol.11
, pp. 197-219
-
-
Wolff, R.1
-
168
-
-
25644437167
-
Dose response of inhaled dry powder insulin and dose equivalence to subcutaneous insulin Lispro
-
Rave KM, Nosek L, de la Pena A, Ernest CS 2nd, Heine-mann L, Batycky RP, and Muchmore DB: Dose response of inhaled dry powder insulin and dose equivalence to subcutaneous insulin Lispro. Diabetes Care. 2005;28:2400-2405.
-
(2005)
Diabetes Care
, vol.28
, pp. 2400-2405
-
-
Rave, K.M.1
Nosek, L.2
De La Pena, A.3
Heine-Mann, L.4
Batycky, R.P.5
Muchmore, D.B.6
-
169
-
-
70349462772
-
Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in pa-tients with type 2 diabetes previously treated with once daily insulin glargine
-
Rosenstock J, Eliaschewitz FG, Hellmann CR, Muchmore DB, Hayes RP, and Belin RM: Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in pa-tients with type 2 diabetes previously treated with once daily insulin glargine. Diabetes Technol Ther. 2009;11:S63-S73.
-
(2009)
Diabetes Technol Ther
, vol.11
-
-
Rosenstock, J.1
Eliaschewitz, F.G.2
Hellmann, C.R.3
Muchmore, D.B.4
Hayes, R.P.5
Belin, R.M.6
-
170
-
-
78650201586
-
AERx pulmonary drug deliv-ery systems
-
MJ Rathbone, J Hadgraft, MS Roberts, and ME Lane (eds)
-
Cipolla D, and Johansson E: AERx pulmonary drug deliv-ery systems. In: MJ Rathbone, J Hadgraft, MS Roberts, and ME Lane (eds). Modified Release Drug Delivery Technology, 2nd ed. pp. 563-571, 2008.
-
(2008)
Modified Release Drug Delivery Technology, 2nd Ed
, pp. 563-571
-
-
Cipolla, D.1
Johansson, E.2
-
171
-
-
0034043186
-
Pulmonary insulin adminis-tration using the AERx system: Physiological and physico-chemical factors influencing insulin effectiveness in healthy fasting subjects
-
Farr S, McElduff A, Mather L, Okikawa J, Ward ME, Gonda I, Licko V, and Rubsamen RM: Pulmonary insulin adminis-tration using the AERx system: physiological and physico-chemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther. 2000;2:185-197.
-
(2000)
Diabetes Technol Ther
, vol.2
, pp. 185-197
-
-
Farr, S.1
McElduff, A.2
Mather, L.3
Okikawa, J.4
Ward, M.E.5
Gonda, I.6
Licko, V.7
Rubsamen, R.M.8
-
172
-
-
78650206628
-
Pulmonary delivery of insulin using the asthma platform model
-
RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
-
Genova P, Buchwald A, McGovern M, et al.: Pulmonary delivery of insulin using the asthma platform model. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 537-539, 2004.
-
(2004)
Respiratory Drug Delivery IX
, pp. 537-539
-
-
Genova, P.1
Buchwald, A.2
McGovern, M.3
-
173
-
-
33745000699
-
Triple therapy in type 2 diabetes: Insulin glargine or rosglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients
-
Rosenstock J, Sugimoto D, Strange P, Stewart JA, Solter-Rak E, and Dailey G: Triple therapy in type 2 diabetes: insulin glargine or rosglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554-559.
-
(2006)
Diabetes Care
, vol.29
, pp. 554-559
-
-
Rosenstock, J.1
Sugimoto, D.2
Strange, P.3
Stewart, J.A.4
Solter-Rak, E.5
Dailey, G.6
-
174
-
-
16344387901
-
Patient outcomes in the GH monitor: The effect of delivery device on compliance and growth
-
Desrosiers P, O'Brien F, and Blethen S. Patient outcomes in the GH monitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2005; 2(Suppl 3): 327-331.
-
(2005)
Pediatr Endocrinol Rev
, vol.2
, Issue.SUPPL. 3
, pp. 327-331
-
-
Desrosiers, P.1
O'Brien, F.2
Blethen, S.3
-
175
-
-
68249149677
-
Short-term safety of somatropin inhala-tion powder in adults with mild to moderate asthma
-
Nelson HS, Busse WW, Sanger M, Cutler G, Ellwanger C, and Chipman JJ: Short-term safety of somatropin inhala-tion powder in adults with mild to moderate asthma. Al-lergy Asthma Proc. 2009;30:325-332.
-
(2009)
Allergy Asthma Proc.
, vol.30
, pp. 325-332
-
-
Nelson, H.S.1
Busse, W.W.2
Sanger, M.3
Cutler, G.4
Ellwanger, C.5
Chipman, J.J.6
-
176
-
-
66749113520
-
Short-term safety of somatropin inhalation powder in adults with mild to moderate asthma
-
Walvoord EC, de la Pena A, Park S, Silverman B, Cuttler L, Rose SR, Cutler G, Drop S, Chipman JJ: Short-term safety of somatropin inhalation powder in adults with mild to moderate asthma. J Clin Endocrinol Metab 2009; 94: 2052-2059.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 2052-2059
-
-
Walvoord, E.C.1
De La Pena, A.2
Park, S.3
Silverman, B.4
Cuttler, L.5
Rose, S.R.6
Cutler, G.7
Drop, S.8
Chipman, J.J.9
-
177
-
-
78650225432
-
Evaluation of the AERx system for the pulmonary delivery of recombinant human interferon alfa-2b to healthy subjects
-
Seoul, South Korea, July
-
Balwani G, Boyd B, Whatley J, Thipphawong J, Morishige R, Okikawa J, Otulana B, Tamches E, Buclin T, Biollaz J, Spertini F, and Gonda I: Evaluation of the AERx system for the pulmonary delivery of recombinant human interferon alfa-2b to healthy subjects. International Controlled Release Society Meeting, Seoul, South Korea, July 2002.
-
(2002)
International Controlled Release Society Meeting
-
-
Balwani, G.1
Boyd, B.2
Whatley, J.3
Thipphawong, J.4
Morishige, R.5
Okikawa, J.6
Otulana, B.7
Tamches, E.8
Buclin, T.9
Biollaz, J.10
Spertini, F.11
Gonda, I.12
-
178
-
-
0028129568
-
Effect of aero-solized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in pa-tients with cystic fibrosis
-
for the Pulmozyme Study Group
-
Fuchs HJ, Borowitz DH, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, and Wohl ME, for the Pulmozyme Study Group et al: Effect of aero-solized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in pa-tients with cystic fibrosis. N Engl J Med. 1994;331:637-642.
-
(1994)
N Engl J Med
, vol.331
, pp. 637-642
-
-
Fuchs, H.J.1
Borowitz, D.H.2
Christiansen, D.H.3
Morris, E.M.4
Nash, M.L.5
Ramsey, B.W.6
Rosenstein, B.J.7
Smith, A.L.8
Wohl, M.E.9
-
179
-
-
0020611430
-
Successful im-munization of children with and without maternal anti-body by aerosolized measles vaccine
-
Sabin AB, Arechiga AF, Fernandez de Castro J, Sever JL, Madden DL, Shekarchi I, and Albrecht P: Successful im-munization of children with and without maternal anti-body by aerosolized measles vaccine. JAMA. 1983;249: 2651-2662.
-
(1983)
JAMA
, vol.249
, pp. 2651-2662
-
-
Sabin, A.B.1
Arechiga, A.F.2
Fernandez De Castro, J.3
Sever, J.L.4
Madden, D.L.5
Shekarchi, I.6
Albrecht, P.7
-
180
-
-
33947203155
-
Drying-induced variations in physico-chemical properties of amorphous pharmaceuti-cals and their impact on stability II: Stability of a vaccine
-
Abdul-Fattah AM, Truong-Le V, Yee L, Pan E, Ao Y, Ka-lonia DS, and Pikal MJ: Drying-induced variations in physico-chemical properties of amorphous pharmaceuti-cals and their impact on stability II: stability of a vaccine. Pharm Res. 2007;24:715-727.
-
(2007)
Pharm Res
, vol.24
, pp. 715-727
-
-
Abdul-Fattah, A.M.1
Truong-Le, V.2
Yee, L.3
Pan, E.4
Ao, Y.5
Ka-Lonia, D.S.6
Pikal, M.J.7
-
181
-
-
0037836974
-
Evaluation of novel aerosol formulations designed for mucosal vaccina-tion against influenza virus
-
Smith DJ, Bot S, Dellamary L, and Bot A: Evaluation of novel aerosol formulations designed for mucosal vaccina-tion against influenza virus. Vaccine. 2003;21:2805-2812.
-
(2003)
Vaccine
, vol.21
, pp. 2805-2812
-
-
Smith, D.J.1
Bot, S.2
Dellamary, L.3
Bot, A.4
-
182
-
-
42649090103
-
Safety evaluation of pulmonary influenza vaccination in healthy and asthmatic mice
-
Minne A, Huaux F, Jaworska J, Rha RD, Hamelmann E, and Vanbever R: Safety evaluation of pulmonary influenza vaccination in healthy and asthmatic mice. Vaccine. 2008;26:2360-2368.
-
(2008)
Vaccine
, vol.26
, pp. 2360-2368
-
-
Minne, A.1
Huaux, F.2
Jaworska, J.3
Rha, R.D.4
Hamelmann, E.5
Vanbever, R.6
-
183
-
-
43049120930
-
Development of stable influenza vaccine powder formulations: Challenges and possibilities
-
Amorij J-P, Huckriede A, Wilschut J, Frijlink HW, and Hinrichs WL: Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25:1256-1273.
-
(2008)
Pharm Res
, vol.25
, pp. 1256-1273
-
-
Amorij, J.-P.1
Huckriede, A.2
Wilschut, J.3
Frijlink, H.W.4
Hinrichs, W.L.5
-
184
-
-
30444434900
-
A randomized trial of inhaled cyclosporine in lung transplant recipients
-
Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, and Griffith BP: A randomized trial of inhaled cyclosporine in lung transplant recipients. N Engl J Med. 2006;354:141-150.
-
(2006)
N Engl J Med
, vol.354
, pp. 141-150
-
-
Iacono, A.T.1
Johnson, B.A.2
Grgurich, W.F.3
Youssef, J.G.4
Corcoran, T.E.5
Seiler, D.A.6
Dauber, J.H.7
Smaldone, G.C.8
Zeevi, A.9
Yousem, S.A.10
Fung, J.J.11
Burckart, G.J.12
McCurry, K.R.13
Griffith, B.P.14
-
185
-
-
33846907545
-
Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
-
Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, and Hartl D: Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007;29:240-250.
-
(2007)
Eur Respir J
, vol.29
, pp. 240-250
-
-
Griese, M.1
Latzin, P.2
Kappler, M.3
Weckerle, K.4
Heinzlmaier, T.5
Bernhardt, T.6
Hartl, D.7
-
187
-
-
0035140471
-
Pulmonary effects of inhaled ultrafine particles
-
Oberdorster G: Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health. 2001;74:1-8.
-
(2001)
Int Arch Occup Environ Health
, vol.74
, pp. 1-8
-
-
Oberdorster, G.1
-
189
-
-
0034860506
-
Receptor-mediated targeting of spray-dried lipid particles co-formulated with lipid immunoglobulin loaded with a prototype vaccine
-
Bot AI, Smith DJ, Bot S, Dellamary L, Tarara TE, Harders S, Phillips W, Weers JG, and Woods CM: Receptor-mediated targeting of spray-dried lipid particles co-formulated with lipid immunoglobulin loaded with a prototype vaccine. Pharm Res. 2001;18:971-979.
-
(2001)
Pharm Res
, vol.18
, pp. 971-979
-
-
Bot, A.I.1
Smith, D.J.2
Bot, S.3
Dellamary, L.4
Tarara, T.E.5
Harders, S.6
Phillips, W.7
Weers, J.G.8
Woods, C.M.9
|